1509 related articles for article (PubMed ID: 11076429)
21. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
[TBL] [Abstract][Full Text] [Related]
22. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
23. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
24. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
25. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
26. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
27. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Coiffier B; Khayat D; Misset JL; Votan B
Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
[TBL] [Abstract][Full Text] [Related]
28. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
29. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
31. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
[TBL] [Abstract][Full Text] [Related]
32. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
33. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M
Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254
[TBL] [Abstract][Full Text] [Related]
34. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
[TBL] [Abstract][Full Text] [Related]
35. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
36. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
[TBL] [Abstract][Full Text] [Related]
37. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
[TBL] [Abstract][Full Text] [Related]
38. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
Abbott B; Ippoliti C; Bruton J; Neumann J; Whaley R; Champlin R
Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
[TBL] [Abstract][Full Text] [Related]
39. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Spitzer TR; Friedman CJ; Bushnell W; Frankel SR; Raschko J
Bone Marrow Transplant; 2000 Jul; 26(2):203-10. PubMed ID: 10918432
[TBL] [Abstract][Full Text] [Related]
40. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
Gralla RJ; Navari RM; Hesketh PJ; Popovic W; Strupp J; Noy J; Einhorn L; Ettinger D; Bushnell W; Friedman C
J Clin Oncol; 1998 Apr; 16(4):1568-73. PubMed ID: 9552067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
